HAE — HAEMONETICS CORPORATION (Healthcare >> Medical Devices)
HAE FAQ
What is HAE's P/E ratio?
HAEMONETICS CORPORATION (HAE) currently trades at a P/E ratio of 27.49.
What is HAE's ROE?
HAEMONETICS CORPORATION reports a Return on Equity (ROE) of 12.22%.
What is HAE's dividend yield?
HAEMONETICS CORPORATION offers a dividend yield of 0.00%.
What is HAE's Deepscope Quality Score?
Deepscope rates HAE's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy HAE?
Deepscope's AI Timing Score for HAE is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does HAE belong to?
HAEMONETICS CORPORATION is classified under the Healthcare >> Medical Devices sector on the NYSE exchange.
|
USD 69.85
Price
3.97
(6.03%)
Day Change
|
|
|---|
HAE, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
1585
|
| Magic Formula Rank by ROE |
1585
|
| Magic Formula Rank by ROIC |
1606
|
| Price | 69.85 |
| PBV / Sector |
4.05 / 7.50
|
| Earning Per Share | 2.05 |
| PE / Sector |
27.49 / 28.68
|
| PEG or PE/Growth / Sector |
1.18 / 0.39
|
| Average 1M Daily Value |
61.88 M
|
| Average 1W Daily Value |
61.69 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
62% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-05 09:12:16 |
| Symbol | HAE |
| Name | HAEMONETICS CORPORATION |
| Sector | Healthcare >> Medical Devices |
| Market | NYSE |
| Listed Shares | 45.45 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,228.75 / 18,060.39 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 125 Summer Street, Boston, MA, United States, 02110
Phone: 781 848 7100
Website: https://www.haemonetics.com
Employees: 3,009
Sector: Healthcare >> Medical Devices
Description: Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
Google